Identifying key molecules that launch regeneration has been a long-sought goal. Multiple regenerative animals show an initial wound-associated proliferative response that transits into sustained proliferation if a considerable portion of the body part has been removed 1-3 . In the axolotl, appendage amputation initiates a round of wound-associated cell cycle induction followed by continued proliferation that is dependent on nerve-derived signals 4,5 . A wound-associated molecule that triggers the initial proliferative response to launch regeneration has remained obscure. Here, using an expression cloning strategy followed by in vivo gain-and lossof-function assays, we identified axolotl MARCKS-like protein (MLP) as an extracellularly released factor that induces the initial cell cycle response during axolotl appendage regeneration. The identification of a regeneration-initiating molecule opens the possibility of understanding how to elicit regeneration in other animals.
Identifying key molecules that launch regeneration has been a long-sought goal. Multiple regenerative animals show an initial wound-associated proliferative response that transits into sustained proliferation if a considerable portion of the body part has been removed 1-3 . In the axolotl, appendage amputation initiates a round of wound-associated cell cycle induction followed by continued proliferation that is dependent on nerve-derived signals 4, 5 . A wound-associated molecule that triggers the initial proliferative response to launch regeneration has remained obscure. Here, using an expression cloning strategy followed by in vivo gain-and lossof-function assays, we identified axolotl MARCKS-like protein (MLP) as an extracellularly released factor that induces the initial cell cycle response during axolotl appendage regeneration. The identification of a regeneration-initiating molecule opens the possibility of understanding how to elicit regeneration in other animals.
To identify a regeneration-initiating molecule in the salamander Ambystoma mexicanum (axolotl), we aimed to functionally screen 6, 7 axolotl complementary DNAs using an in vitro salamander myotube cell cycle re-entry assay (Notophthalmus viridescens; newt) 8 with the aim of performing in vivo analysis in the axolotl that is convenient for molecular analysis [9] [10] [11] . To establish if axolotl blastema tissue expresses a myotube cell-cycle-entry inducing factor, we injected Xenopus oocytes with messenger RNAs from tail blastema, limb blastema or mature limb and assayed the extracellular media on myotubes ( Fig. 1a ). Tail or limb blastema mRNAs scored positively, comparable to serum, whereas the mature tissue mRNAs showed little inducing activity. We next screened an arrayed 6-day tail blastema cDNA eukaryotic expression vector library for the activity 12 . Transfection of DNA representing the entire library as a single pool into HEK293 cells ( Fig. 1b , sample WL) yielded cell media that stimulated myotube cell cycle entry (Fig. 1b ). This library was fractionated into 12 superpools, which yielded four positive superpools (superpool numbers 6, 9, 10 and 12; Fig. 1b and Extended Data Fig. 1a-f ). Sib-selection of superpool 9 through three subfractionation steps resulted in identification of a single clone responsible for the activity (Extended Data Fig. 2a-c) .
The positive clone encoded a 224-amino-acid protein containing three conserved domains (myristoylated N terminus, MARCKS homology domain and effector domain) similar to MLP (Extended Data Fig. 3a) showing 74.1%, 68.0% and 80.0% amino acid sequence identity to human MLP (also known as MARCKSL1), including the glycine G2 in the myristoylated domain and two serines in the effector domain (S94 and S105) important for plasma membrane binding (for review see ref. 13 ). The C-terminal region showed low (14.4%) sequence conservation. Phylogenetic analysis showed that the axolotl sequence clustered with other vertebrate MLPs (Extended Data Fig. 3b ).
Previous work in other species has indicated that MLP is an intracellular substrate for protein kinase C (PKC) associated with the plasma membrane, phagocytic vesicles and actin, while phosphorylation by PKC induced dissociation to the cytoplasm (for review see ref. 14) . We asked whether axolotl MLP (AxMLP) acted on myotubes as a secreted factor or whether it induced expression of a secreted factor in the HEK293 cells. To determine if AxMLP was extracellularly released, we transfected an expression plasmid encoding an AxMLP-C-terminal fusion with enhanced GFP (eGFP) or the pEGFP-N1 control construct into HEK293 cells (Extended Data Fig. 3c ). Increasing levels of GFP fluorescence intensity were observed in AxMlp-eGfp-transfected but not eGfp-N1-transfected culture media (Fig. 1c ). The percentage of GFP + cells and the total cell number in AxMlp-eGfp-and eGfp-N1-transfected samples remained equivalent over time (Extended Data Fig. 3d, e ). Time-lapse imaging further showed that AxMlp-eGfptransfected cells grew similarly to the control cells (Supplementary Videos 1 and 2), indicating that extracellular AxMLP did not derive from dying cells. When comparing expression of AxMLP to zebrafish, Xenopus, mouse, newt and human MLPs in HEK293 cells, we observed that the AxMLP yielded a higher proportion of extracellular protein compared with other species (Fig. 1d ). Bioassay of the axolotl versus newt MLP media induced a myotube response corresponding to the amount of protein seen by western blot (Fig. 1e ).
To establish necessity, we exposed AxMLP-containing culture media to a polyclonal antibody against AxMLP that inhibited the myotube response, indicating that extracellular AxMLP is required for the activity (Fig. 1f and Extended Data Fig. 3f ). To test sufficiency, we purified AxMLP-His, which displayed a characteristic high gel mobility (Extended Data Fig. 3g , h; for review see ref. 13 ). Exposure of myotubes to purified AxMLP in serum-free conditions yielded a robust myotube response with an approximate half-maximal response at 50.5 ng μl −1 ( Fig. 1g and Extended Data Fig. 2d-f ). We conclude that extracellular AxMLP is sufficient to induce myotube cell cycle re-entry.
To determine the in vivo function of extracellular AxMLP, we first queried whether purified AxMLP protein injected into uninjured axolotl tail ( Fig. 2 ) and limb (Extended Data Fig. 4 ) tissue was sufficient to induce cell cycle re-entry. We injected 270 ng of AxMLP followed by injection of 5-bromodeoxyuridine (BrdU) at 3 days post-amputation (dpa) ( Fig. 2a and Extended Data Fig. 4e ). AxMLP-injected tails contained significantly more BrdU-positive cells (18.9 ± 2.59%) than control tails injected with media depleted of AxMLP (flow-through, 3.20 ± 0.863%; PBS, 3.04 ± 1.00%) ( Fig. 2b-d ). AxMLP injection caused increased BrdU uptake in all counted cell types in limbs and tails except for myocyte enhancer factor 2C (MEF2C) + muscle nuclei ( Fig. 2b-d and Extended Data Fig. 4a -d, f-n). Interestingly, it was recently found that muscle fibres can dedifferentiate during newt limb regeneration, but not in axolotl 15 . The responsiveness of axolotl PAX7 + satellite cells but not MEF2C + muscle nuclei to AxMLP corresponds with PAX7 + satellite cells being the main contributors to muscle regeneration in axolotl 15 .
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As we had used the newt myogenic cell line for the original screen, we asked whether AxMLP could promote in vivo cell cycle entry during muscle dedifferentiation in the newt. AxMLP protein was injected either into uninjured newt limbs or after limb amputation during the muscle dedifferentiation phase ( Fig. 3 ). Injection of AxMLP into uninjured newt tissue was not sufficient to induce a cell cycle response ( Fig. 3a ). Injection during regeneration, however, resulted in an increased 5-ethynyldeoxyuridine (EdU) uptake in PAX7 + satellite cells as well as dedifferentiating myofibre-derived cells (Fig. 3b , c) 15 . These data indicate that AxMLP can also promote cell cycle entry of at least two cell types in newt, including dedifferentiating muscle. The requirement for an additional injury signal to induce cell cycle entry in newt correlates with a higher propensity of axolotl stem cells to cycle in homeostasis compared with their newt counterparts 16, 17 .
We next asked if AxMLP is important for cell proliferation during axolotl regeneration. Microarray and quantitative reverse transcription polymerase chain reaction (qRT-PCR) detected expression in mature limb and tail tissue followed by upregulation with a peak of expression at 12 to 24 h post-amputation (hpa), returning to basal levels at 2 dpa in the tail and 4 dpa in the limb (Extended Data Fig. 5a , e). These observations are consistent with a role for AxMLP in early events of regeneration. Protein localization using immunofluorescence showed that in uninjured tissue, AxMLP was cytoplasmically localized in epidermis and in tail spinal cord cells, including radial glia and axonal tracts (Extended Data Fig. 5b , f, high-magnification images). At 1 and 6 dpa, expression was maintained in the epidermis and spinal cord (Extended Data Fig. 5c, d , g, h, high-magnification images). However, the protein in the regenerating wound epidermis at 1 dpa was plasma-membrane associated (Extended Data Fig. 5c , g, green arrowheads in high magnification images). Such localization changes have previously been described for MARCKS proteins and are dependent on phosphorylation state 18 . In summary, AxMLP protein is To test the function of endogenous AxMLP during regeneration, we implemented two different fluorescein isothiocyanate (FITC)conjugated morpholinos directed against 5′ sequences of the AxMlp mRNA. We validated the effectiveness of the morpholinos in vitro by co-electroporation with plasmid encoding full-length AxMlp or ΔN-terminal-AxMlp-His lacking the target sequence into cultured newt cells (Extended Data Fig. 6a , k). Immunostainings and western blots showed that the morpholinos strongly reduced AxMLP expression but did not affect the expression of ΔN-AxMLP (Extended Data Fig. 6b -j, l-s). No effects were observed with two different negative control morpholinos including a five-mismatch morpholino (Extended Data Fig. 6b -j, l-s).
To knockdown AxMLP in vivo, we electroporated AxMlp or control morpholinos into the tail epidermis and spinal cord 3 days before amputation. Reduction of protein levels in electroporated cells was confirmed by immunostaining (Extended Data Fig. 7 ). To test whether exogenously provided AxMLP protein would rescue the knockdown phenotype, the electroporated tails were injected at 1 dpa with purified 
AxMLP or inactive flow-through. Blastema length was measured at 1, 3, 6, 10 and 14 dpa, and BrdU incorporation was assayed at 3 dpa ( Fig. 4a and Extended Data Fig. 8f , i). Incorporation of BrdU in the AxMlp morpholino-electroporated samples was significantly reduced ( Fig. 4d and Extended Data Fig. 8a-e ). Correspondingly, at 6 dpa, the blastema length of the AxMlp-morpholino/flow-throughinjected tails was 59% smaller than that of the control morpholino/ flow-through-injected ones (specific/flow-through, 546.7 ± 80.1 μm; control/flow-through, 1,318 ± 206 μm; Fig. 4b, c ). In contrast, AxMlpmorpholino-electroporated tails injected with purified AxMLP protein showed a 50% rescue in blastema length and 85% rescue of BrdU incorporation (Fig. 4c, d ). The partial rescue in blastema length is probably due to the limited amounts of AxMLP provided by a single injection. The specificity of the phenotype was confirmed by implementing the second morpholino and the control five-mismatch morpholino (Extended Data Fig. 8g-j) . These results show that knockdown of AxMLP via morpholino results in reduced cell proliferation that can be rescued by provision into the muscle/blastema tissue of exogenous AxMLP protein.
To corroborate the morpholino experiments, we injected the anti-AxMLP blocking antibody into the tail before and during regeneration (Extended Data Fig. 9a ), which strongly reduced BrdU incorporation in multiple tissues ( Fig. 4e -g and Extended Data Fig. 9b ). These results show that in vivo knockdown of AxMLP activity by two methods resulted in reduced cell proliferation during early regeneration.
To determine if an excess of AxMLP could accelerate regeneration, we performed multiple injections of AxMLP protein before and during early phases of regeneration (Extended Data Fig. 10a ). The oversupply of protein resulted in a larger blastema at 4 dpa (Extended Data Fig. 10b, c) .
This work represents the first identification of a molecule, AxMLP, by functional expression cloning and in vivo testing in appendage regeneration and therefore sets an experimental paradigm for future studies. Previous work indicated that spinal cord neural stem cells accelerate their cell cycle kinetics resulting in increased mitoses between 3 and 4 dpa (ref. 19 ). Our work indicates that AxMLP is a major factor responsible for the induction of these cell cycle kinetics. How AxMLP is delivered extracellularly, its mode of intracellular signalling and whether orthologues beyond salamanders are associated with regenerative events will be important topics of future investigation.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Letter reSeArCH MethODS Animals. All animal experiments were performed in accordance with the European Community and local ethics committee guidelines. Xenopus laevis were purchased (Nasco) and maintained in our animal facility. Ambystoma mexicanum (axolotls) were bred and maintained in our facility, where they were kept at 18 °C in Dresden tap water and fed daily with artemia or fish pellets. Five-to-six centimetre (snout to tail tip) axolotls were used for all the experiments. Animals were anaesthetized for all the surgical process as previously described 20 . Labelling of connective tissue was achieved by transplanting lateral plate mesoderm from GFP transgenic embryos to normal host embryos as previously described 20 . Protein expression by Xenopus oocytes. Total RNA was isolated from day-1, day-3 and day-5 limb and tail blastemas with TRIzol reagent (Invitrogen) according to the manufacturer's manual. Total RNA from mature (not regenerating) limb tissues was isolated using the same procedure as blastema samples. Blastema RNAs from the different time points were equivalently pooled as limb-blastema total RNA or tail-blastema total RNA, respectively. mRNA was purified from limbblastema or tail-blastema total RNA with the Poly (A) Quick mRNA isolation kit (Stratagene). Xenopus oocyte preparation and microinjection were performed essentially as previously described 6, 7, 21 . Briefly, mature oocytes were defolliculated with collagenase (Sigma). Purified mRNA (5.0 ng) was injected into the selected healthy oocytes after the defolliculation. Eight injected oocytes were cultured together in one well of a 96-well plate (Nunc) for 48 h and the supernatants were harvested for myotube assay (see later). Functional expression cloning. Clones (110,592) from a 6-day tail blastema library were arrayed into 288 × 384-well plates 22 . To prepare the 'pools' , all the saturated bacterial cultures on one 384-well plate were pooled in one conical tube, and 288 pools were prepared from the library in total. To prepare the 'superpools' , 24 pools were combined together in one conical tube, and 12 superpools were prepared from the pools in total (Extended Data Fig. 1a-c) . To obtain superpool plasmid, 500 μl of superpool bacteria were cultured in 50 ml LB medium (Extended Data Fig. 1d ). To avoid losing low frequency clones in the superpools, the optical density (OD) of each culture was controlled and the cultures were harvested around OD 600 nm 0.6. Superpool plasmids were purified with QIAGEN Plasmid Midi Kit (QIAGEN) according to the manufacturer's manual. To reconstitute the whole library, 5 μg of each superpool's plasmids were pooled in one tube before transfection. HEK293FT cells (Invitrogen) were maintained with the standard protocol from Invitrogen. To obtain the superpool supernatants, 8.0 × 10 5 of HEK293 cells were plated on one well of a 6-well plate (Nunc) and 1 μg of each individual superpool plasmids were transfected into HEK293 cells with Fugene 6 (Roche; Extended Data Fig. 1e ) according to the manufacturer's manual. For the first 24 h, the transfected HEK293 cells were kept in the 10% fetal calf serum (FCS) medium. Then the cells were rinsed with FreeStyle 293 expression medum (Gibco) that is a serumfree medium and cultured in the medium at 72 h after transfection. Individually harvested supernatants were concentrated approximately tenfold with a Vivaspin 10,000 MWCO (Sartorius). These concentrated supernatants were tested on A1 myotubes (Extended Data Fig. 1f ). It should be noted that given the injury-specific extracellular activity of AxMLP, we infer that the Xenopus oocyte and HEK293 cell systems are likely to be in 'wound-epithelium-like' signalling states that permit at least some extracellular release of AxMLP, and that the 6-day regenerating tail blastema cDNA had a sufficient number of AxMLP clones for detection in the expression cloning system. We only detected 1 AxMLP clone among 100,000 clones, and this may reflect the levels of mRNA present at later regeneration time points.
Maintenance of A1 myoblasts, myotube differentiation from A1 myoblasts, myotube purification and subsequent myotube assays were performed essentially as described previously 8, 23, 24 . Briefly, concentrated supernatants were individually added into myotube culture medium in a 96-well plate and incubated for 5 days, and BrdU (Sigma; final 10 μg ml −1 ) was added to the culture media for 18 h before the fixation with 1.5% PFA (Sigma)/PBS. Fixed myotubes were stained with anti-MHC and anti-BrdU antibodies (mouse monoclonal, 4a1025 and Bu20a) conjugated to FITC or rhodamine with DyLight Antibody Labelling Kit (Thermo Scientific) according to the manufacturer's manual. For the quantification of BrdU incorporation activity, the total number of myotubes and BrdU + myotubes were counted by hand under the microscope (Zeiss Axioplan 2). This biological evaluation of the BrdU-incorporation activity on myotubes is called the myotube assay. The high-serum (15% FCS) condition was used as a positive control for myotube assays and the low-serum (0.5% FCS) or serum-free condition was used as a negative control.
For the second screen from superpool number 9, the clones from the 24 384well plates contained in superpool 9 were divided into smaller sub-pools according to a two-dimensional matrix (Extended Data Fig. 2a ). For example, sub-pool A contained pools from plates 193-198 and sub-pool 1 contained pools from plates 193, 199, 205, 211. These sub-pools were cultured to OD 600 nm 0.6 before plasmid preparation. For the third screen from pool number 212, 384 single clones were arrayed by 96-pin plastic replicators (Genetix) on 96-well plates (SARSTEDT) filling 150 μl LB medium per well (Extended Data Fig. 2b ; groups A-D). Individual clones on the 96-well plates were statically cultured until they were saturated and 24 clones were pooled together (Extended Data Fig. 2b ; sub-pools A1-D4). Plasmids from each pool were purified with QIAprep spin miniprep kit (QIAGEN). For the fourth screen from A1, 24 clones were individually cultured in LB medium and the plasmids were purified with QIAprep spin miniprep kit (QIAGEN). To construct sub-pools, 1 μg of the plasmid from each single clone was pooled according to the diagram in Extended Data Fig. 2c . The process from the transfection into HEK293 cells to myotube assay in the second to the fourth screen was the same as the first screen. To validate transfection efficiency during whole expression cloning, 50 pg of secreted alkaline phosphatase (SEAP)-pCMV-SPORT6 plasmid was co-transfected with the samples as a spike and a portion of the supernatants was assayed by Great EscAPe SEAP Chemiluminescence Kit 2.0 (Clontech). The luminescence of the supernatants was measured by GENiosPro Microplate Reader (TECAN). We confirmed that there was no significant difference of transfection efficiency during the expression cloning (data not shown). There were no cell line misidentification and cross-contamination in the experiments. We used a single mammalian cell line (HEK293FT cells) provided by Invitrogen and single amphibian cell line (newt A1 cells) in the experiments. These two cell lines have totally different morphologies and are cultured under mutually incompatible culture conditions. The growth of both cells were carefully monitored during the experiments and cells samples were constantly stained with Hoechst 33342 (Sigma, final 0.5 μg ml −1 ) to test mycoplasma contamination. Plasmid construction. Human and mouse MLP cDNA clones were purchased from OriGene Technologies (clone ID: human, SC112373; mouse, MC208965). Zebrafish and Xenopus mlp cDNA clones were purchased from Source BioScience (clone ID: zebrafish, 6795591; Xenopus, 8330180). All oligonucleotide sequences and the restriction enzyme sites using for cloning are shown in Supplementary  Table 2 . Since the backbone vector of the cDNA library is pCMV-SPORT6, we subcloned following genes into pCMV-SPORT6 vector (Invitrogen) or pCMV-SPORT6-3C-His vector. PCR-amplified fragments with the oligonucleotides numbers 1 and 2 from pSEAP2-Basic (Clontech) were subcloned into pCMV-SPORT6. The oligonucleotides numbers 3 and 4 were attached to pCMV-SPORT6 to generate a backbone vector, pCMV-SPORT6-3C-His (Extended Data Fig. 3c,  bottom left) . The AxMlp open reading frame (ORF) was amplified by PCR with the oligonucleotides numbers 5 and 6 from the original AxMlp clone (BL212a101) and subcloned in the pCMV-SPORT6-3C-His vector (Extended Data Fig. 3c , top left). N-terminal deletion AxMlp was amplified by PCR with the oligonucleotides numbers 7 and 8 from the original AxMlp clone (BL212a101) and subcloned in the pCMV-SPORT6-3C-His vector (Extended Data Fig. 6a, bottom) . Human, mouse, zebrafish and Xenopus MLP ORFs were amplified from purchased cDNA clones with specific primers (for human, oligonucleotides numbers 9, 10; mouse, oligonucleotides numbers 9, 11; zebrafish, oligonucleotides numbers 12, 13; Xenopus, oligonucleotides numbers 14, 15, respectively), and were subcloned in the pCMV-SPORT6-3C-His vector. The oligonucleotides numbers 16 and 17 were inserted into to the pEGFP-N1 plasmid (Clontech) to generate a backbone vector, pEGFP-N1-3C (Extended Data Fig. 3c , bottom right). The AxMlp ORF was amplified by PCR with the oligonucleotides numbers 18 and 19 from the original AxMlp clone (BL212a101) and subcloned into pEGFP-N1-3C (Extended Data Fig. 3c, top right) . Newt Mlp ORF was amplified by PCR from newt limb blastema cDNA with the oligonucleotides numbers 28 and 29 and the PCR fragments were subcloned in the pCMV-SPORT6-3C-His vector. These constructs were confirmed by sequencing. Assessment of AxMLP extracellular secretion. For measuring the GFP intensity of supernatants, 8.0 × 10 5 of HEK293 cells were plated on 6-well plates and 1 μg of AxMLP-3C-pEGFP-N1 plasmid or 1 μg of empty-pEGFP-N1 plasmid were transfected into HEK293 cells. The supernatants were harvested at 24 h post-transfection (hpt), 48 hpt and 72 hpt and concentrated with Vivaspin 10,000 MWCO (Sartorius) individually. The fluorescence intensity was measured using a GENiosPro Microplate Reader (TECAN). To determine the percentage of GFP + cells in the culture, the transfected cells were detached with Trypsin-EDTA (Gibco, final 0.05%)/PBS from the well, then spread on improved Neubauer chamber. The number of GFP + cells and total cells in the grids were counted by hand and the percentage was calculated. Time-lapse imaging was performed under Axiovert 200M (Zeiss) with humidity, temperature and CO 2 control chamber. Images were taken every 30 min from 5 to 72 hpt. Antibody blocking. For the antibody-based blocking assay in vitro, 1 μg of AxMlp-3C-His-pCMV-SPORT6 plasmid or empty-pCMV-SPORT6-3C-His plasmid was transfected into HEK293 cells with Fugene 6 (Roche). The supernatants were harvested at 72 hpt and concentrated. Ten micrograms of AxMLP-3C-His protein Letter reSeArCH (22.7 kDa) were treated with 70 μg or 350 μg of anti-AxMLP polyclonal antibody (see later) or anti-GFP polyclonal antibody (MPI-CBG antibody facility) as a negative control, respectively, at room temperature for 2 h. These antibody-treated supernatants were used for the myotube assay.
For the in vivo antibody blocking assay, anti-full-length AxMLP polyclonal antibody (see later), anti-GFP polyclonal antibody (MPI-CBG antibody facility) or PBS as a negative control were injected into mature (not regenerating) tail as the first injection (3 h before amputation) and injected into the blastema as the second injection (12 h post-amputation) and as the third injection (1 day post-amputation) (Extended Data Fig. 9a ). These samples were co-injected with tetramethylrhodamine dextran MW 70,000 (Molecular Probes; final 2.5 mg ml −1 ) as a tracer. The injection efficiency was confirmed based on the intensity of the rhodamine under the fluorescence dissecting microscope (SZX 16, OLYMPUS). No animals were excluded from the analysis. In each injection 500 ng, then, in total 1.5 μg antibody or equivalent volume of PBS were injected. Injected animals were kept in clean tap water for 3 days at room temperature. The animals were injected intraperitoneally with 30 μl of 2.5 mg ml −1 BrdU (Sigma) 4 h before collecting the tails. The injected blastemas were fixed, embedded, cryosectioned and immunostained as described later. For the imaging, the tiled images of the entire cross-section of the tails taken on a Zeiss Observer.Z1 (Zeiss) were then stitched by Axiovision software or Zen 2 (Zeiss). For the quantification at least a total of 1,000 cells per one animal were counted from four different animals in each condition (PBS, anti-GFP antibody or anti-AxMLP injection, respectively), and the marker-positive nuclei (BrdU + , PAX7 + , MEF2 + or Hoechst + ) on the sections were counted by hand. The cells in spinal cord, epidermis and cartilage/notochord were separately counted based on morphology. The label "Other tissues" in Fig. 2d , contained mainly mesenchymal cells and endothelial cells and was calculated by the subtraction from the total number to the number of all the other specific cell types. AxMLP purification. For His-tagged AxMLP purification, AxMLP-3C-His-pCMV-SPORT6 plasmid was transfected into HEK293 cells and the supernatant was harvested at 72 hpt. His-tagged protein in the supernatant was purified in native conditions on a 1 ml HisTrap HP column (GE Healthcare) using FreeStyle 293 expression medium including 500 mM imidazole step elution. The eluate (purified AxMLP) and depleted media (flow-through) were concentrated with Vivaspin 10,000 MWCO (sartorius) 40 fold and the final concentration of purified AxMLP was 1.31 μg μl −1 . Both concentrated eluate (purified AxMLP) and flow-through fractions were dialysed with Spectra/Por Dialysis Membrane MWCO 6-8000 (Spectrum Laboratories) in AMEM (MEM medium (Gibco) diluted 25% with distilled water) for biological assays. The fractions from the purification were tested by silver staining and western blotting (Extended Data Fig. 3g, h) . The washing fraction was concentrated about tenfold to load the same volume as other fractions on 4-20% gradient SDS-PAGE gels (anamed Elektrophorese). Western blotting and silver staining were performed with a standard protocol. Briefly, the fractions were treated with 2× Sample Buffer including dithiothreitol (DTT; Sigma, final 0.2 M) and boiled at 95 °C for 10 min. The proteins were blotted on PROTRAN nitrocellulose transfer membrane (Whatman) by TE 77 Semi-Dry Transfer Unit (Amersham). The membrane was blocked with 5% skim milk. Primary antibodies used: mouse anti-His (QIAGEN, 1/5,000), mouse anti-α-tubulin (MPI-CBG antibody facility, DM1A 1/5,000), rabbit anti-AxMLP-full length (1/2,500), rabbit anti-AxMLP-C terminus (1/2,500). Secondary antibodies used: goat anti mouse-HRP (Jackson ImmunoResearch Laboratories, 1/5,000), goat anti rabbit-HRP (Jackson ImmunoResearch Laboratories, 1/5,000). Cell lysates for western blotting were obtained by directly adding 2× Sample Buffer on top of the cultured cells and were boiled at 95 °C for 10 min. Antibodies and immunohistochemistry. For the preparation of anti-full-length AxMLP polyclonal antibody, a glutathione S-transferase (GST) fusion protein with full-length amino acids of AxMLP was expressed in bacteria and purified by standard methods on GS-trap, glutathione sepharose (GE Healthcare). Purified GST fusion protein as an antigen was used to immunize rabbits (Charles River). Anti-serum was affinity purified using maltose-binding protein fused with fulllength AxMLP conjugated to NHS-Sepharose resin (GE Healthcare). To raise C-terminal AxMLP polyclonal antibody, keyhole limpet haemocyanin (KLH)tagged peptides, PPVEPQVEEVAAPAP, was used to immunize rabbits and the affinity-purified polyclonal antibody was provided (Eurogentec). Both anti-fulllength and anti-C-terminal AxMLP polyclonal antibodies were tested on the cell lysate from AxMLP-transfected HEK293 cells (Extended Data Fig. 3f) .
Limb blastema and tail blastema preparations for sectioning were produced essentially as previously described 25 . Briefly, limb blastemas amputated at the wrist level were collected from the level of the shoulder, and tail blastemas amputated at the 12th myotome from the cloaca were collected at the 10th myotome of the regenerating tail. These limb and tail blastemas were immunostained as previously described 15, 25, 26 . Briefly, the samples were fixed with MEMFA fixative at 4 °C overnight, and were rinsed with PBS several times. The buffer was replaced from PBS to 10%, 20% and 30% sucrose (Sigma)/PBS, then the samples were embedded in Tissue-Tek O.C.T. Compound (Sakura) for cryosection and the tissues were sectioned at 10-μm thickness with Microm HM 560 cryostat (Thermo). Primary antibodies used: mouse anti-BrdU (MPI-CBG antibody facility, Bu20a 1/400), rabbit anti-BrdU (antibodies-online, 1/600), mouse anti-PAX7 (MPI-CBG antibody facility, PAX7 1/450), rabbit anti-MEF2 (Santa Cruz, 1/200), rabbit anti-AxMLP-C terminus (1/200), rabbit anti-GFP (Rockland, 1/400), rabbit anti-FITC (Invitrogen, 1/400), mouse anti-FITC (Jackson ImmunoResearch Laboratories, 1/400), rat anti-MBP (GeneTex, 1/200). The following appropriate fluorophore-conjugated secondary antibodies were used (all in 1/200 dilution): donkey anti-mouse Alexa Fluor (AF) 647 (Molecular Probes), goat anti-mouse AF 647 (Jackson ImmunoResearch Laboratories), donkey anti-mouse AF 488 (Molecular Probes), goat anti-rabbit AF 647 (Jackson ImmunoResearch Laboratories), donkey anti-rabbit AF 488 (Molecular Probes), donkey anti-rat AF 488 (Molecular Probes). The cell nuclei were stained with Hoechst 33342 (Sigma, final 0.5 μg ml −1 ). Imaging for the stained sections was performed with Zeiss Observer.Z1 (Zeiss) controlled by Axiovision software or Zen2 (Zeiss). qRT-PCR. Total RNA preparation, reverse transcription and qRT-PCR were essentially described in the previous work 2 . Briefly, three biological replicas were prepared for each time point and they were technically independent in all the processes (tissue collection, RNA preparation, cDNA synthesis and qRT-PCR). Eight to approximately ten limb or tail blastemas from one time point were collected in one tube and homogenized by POLYTRON PT1600E (KINEMATICA). Total RNA was purified with RNeasy Mini or Midi Kit (QIAGEN) according to the manufacturer's manual. cDNA was synthesized from 300 ng of total RNA using SuperScript III First-Strand Synthesis System (Invitrogen) and qRT-PCR was performed with Power SYBR Green Master Mix (Invitrogen) in total volume of 12 μl with the final primer concentration of 300 nM on the LightCycler 480 (Roche). To obtain the values of fold change for each time point, the relative concentration of the PCR products was calculated by the standard curve method. To obtain the standard curves of the limb time course or the tail time course respectively, the dilution series (1/4, 1/16, 1/64, 1/256 and 1/1,024) were made from the mixture of cDNAs that were equivalently collected from the cDNA samples in all the different time points. These dilution series were used as the template for the PCR and the relative concentrations were calculated by LightCycler 480 Software (Roche) based on the standard curves. The concentration of AxMlp was normalized with that of Rpl4 (large ribosomal protein 4). Primers used for PCR were showed in Supplementary Table 2 (for AxMlp, oligonucleotides numbers 20, 21; for Rpl4, oligonucleotides numbers 22, 23) . The raw values of qPCR data are shown in Supplementary Table 1 . Protein injection into axolotl tail and limb. The dialysed protein samples: purified AxMLP, depleted media (flow-through) (see earlier) or PBS as a negative control were injected into mature (not regenerating) tails with a pressure injector, PV830 Pneumatic Picopump (World Precision Instruments). These protein samples were co-injected with tetramethylrhodamine dextran MW 70,000 (Molecular Probes, final 2.5 mg ml −1 ) as a tracer. A glass capillary (Harvard Apparatus) for the injection was pulled with P-97 Micropipette Puller (Sutter Instrument) and sharpened manually (external tip diameter: 30 μm). The injection efficiency was confirmed based on the intensity of the rhodamine under the fluorescence dissecting microscope (SZX 16, OLYMPUS). No animals were excluded from the analysis. In total, 270 ng of purified AxMLP or equivalent volume of controls were injected into one side of the tail. Injected animals were kept in clean tap water for 3 days at room temperature. The animals were injected intraperitoneally with 30 μl of 2.5 mg ml −1 BrdU (Sigma) 4 h before collecting the tails (Fig. 2a) . The injected part of the tails was identified by rhodamine-positive myotomes and these tails were fixed, embedded, cryosectioned and immunostained as described earlier. For the quantification, the tile images of whole cross-sections of the tails from Zeiss Observer.Z1 (Zeiss) were stitched by Axiovision software (Zeiss). Three sections from five different animals in each condition (PBS, flow-through or purified AxMLP injection, respectively) were taken, and the marker-positive nuclei (BrdU + , PAX7 + , MEF2 + or Hoechst + ) on the sections were counted by hand. The cells in spinal cord, epidermis and notochord were separately counted based on morphology. The label "Other tissues", contained mainly mesenchymal cells and endothelial cells, and was calculated by the subtraction from the total number to the number of all the other specific cell types.
For the protein injection into the limb, the procedure was essentially as described earlier. Purified AxMLP protein was injected into the mature (not regenerating) right lower limbs at the centre between the elbow and the wrist. The control samples (flow-through fraction or PBS) were injected into the left limbs of the same animal that were injected with purified AxMLP on their right limbs. In total 2.0 μg purified AxMLP or equivalent volume of controls were injected into the limbs. The animals were injected intraperitoneally with 30 μl of 2.5 mg ml −1 BrdU (Sigma) 12 h before collecting the limbs (Extended Data Fig. 4e ). For the quantification, at least a total of 1,000 cells per one animal were counted from four different animals in each condition (PBS, flow-through or purified AxMLP injection, respectively), and the marker-positive nuclei (BrdU + , PAX7 + , MEF2 + , MBP + or Hoechst + ) on the sections were counted by hand. The cells in epidermis and bone/perichondrium were separately counted with their morphology. The label "Other tissues", contained mainly mesenchymal cells and endothelial cells, and was calculated by the subtraction from the total number to the number of all the other specific cell types.
For the acceleration experiment, purified AxMLP, flow-through or PBS as a negative control were injected into mature (not regenerating) tail as the first (3 days before amputation) injection and as the second (1 day before amputation) injection and injected into the blastema as the third (2 days post-amputation) injection (Extended Data Fig. 10a ). These samples were co-injected with tetramethylrhodamine dextran MW 70,000 (Molecular Probes, final 2.5 mg ml −1 ) as a tracer. The injection efficiency was confirmed based on the intensity of the rhodamine under the fluorescence dissecting microscope (SZX 16, OLYMPUS). No animals were excluded from the analysis. The samples were injected into both side of the tail and in each injection, 600 ng, then, in total 1.8 μg protein or equivalent volume of controls were injected. Injected animals were kept in clean tap water for 4 days at room temperature. The length of the blastema was measured from the amputation plane to the tip at the spinal cord level at 4 dpa based on the stereoscope images (SZX 16, OLYMPUS). Morpholino electroporation. In vitro assay. A1 myoblasts were transfected with original clone BL212a101, AxMLP-3C-His, ΔN-AxMLP-3C-His or empty pCMV-SPORT6-3C-His plasmids and co-transfected with AxMLP-specific morpholinos (Gene Tools; Supplementary Table 2 : oligonucleotides numbers 24, 26) or control morpholinos (Gene Tools; Supplementary Table 2 : oligonucleotides numbers 25, 27) using Microporator (Digital Bio) according to the manufacturer's manual with some modifications. All morpholinos were modified with FITC at the 3′ end. A1 myoblasts were re-suspended in 1× Steinberg solution at a density of 5.0 × 10 6 cells per ml followed by incubation of 10 μl cell suspension with 0.5 μg of plasmid and 1 μl of the morpholino (final 100 μM in the incubation). Electroporation was performed at 1,000 V, 35 mS pulse length and 3 pulses and the electroporated cells were spread in 10% FCS AMEM media 24 on a 24-well plate (Nunc), immediately after the electroporation. The culture medium was replaced by new media at 24 h post-electroporation and the cells were kept in culture at 72 h post-electroporation. The electroporated cells were fixed with 1.5% PFA/PBS, and the cell lysates were prepared for western blotting. Primary antibodies used for immunostaining: mouse anti-His (QIAGEN, 1/200), mouse anti-FITC (Jackson ImmunoResearch Laboratories, 1/400), rabbit anti-FITC (Invitrogen, 1/400), rabbit anti-AxMLPfull length (1/1,000). Secondary antibodies used for immunostaining (all in 1/250 dilution): goat anti-mouse Cy3 (Jackson ImmunoResearch Laboratories), goat antimouse AF488 (Jackson ImmunoResearch Laboratories), donkey anti-rabbit AF 488 (Molecular Probes), goat anti-rabbit Cy3 (Jackson ImmunoResearch Laboratories). Images of the stained cells were taken with Zeiss Observer.Z1 (Zeiss) controlled by Axiovision software (Zeiss). In vivo assay with rescue protein injection. Electroporation to the spinal cord was performed as previously described with some modifications 27 . To deliver morpholino into the spinal cord and both sides of the tail epidermis, the tail required electroporation twice with NEPA 21 electroporator (Nepa Gene). The first electroporation was for the spinal cord and one side (left) of the epidermis, and the second electroporation was for the other side (right) of the epidermis. 1.5 μl of morpholino (1.0 mM) was loaded onto a small piece of tissue paper on the left side of the epidermis. Approximately 3 μl of morpholino (1.0 mM) was injected into the spinal cord and immediately electroporated (first electroporation). Sequentially, 1.5 μl of morpholino (1.0 mM) was loaded onto a small piece of tissue paper on the right side of the epidermis and electroporated (second electroporation). The first electroporation conditions: poring pulse, 70 V, 5.0 mS pulse length and 1 pulse; transfer pulse, 55 V, 55 mS pulse length, 5 pulses and 15% decay. The second electroporation conditions: poring pulse, 70 V, 10 mS pulse length and 1 pulse; transfer pulse, 30 V, 30 mS pulse length, 7 pulses and 5% decay. FITC dextran MW 70,000 (Molecular Probes, final 5 mg ml −1 ) was used as a negative control, since morpholinos were labelled with FITC. The electroporation efficiency in the spinal cord and epidermis was examined based on the intensity of the FITC under the fluorescence dissecting microscope (SZX 16, OLYMPUS). The animals with low FITC intensity were excluded from the next step of the experiments. Three days post-electroporation, the tails were amputated at the level of the maximal morpholino electroporated part. One day post-amputation, a total of 360 ng (180 ng for the spinal cord and 180 ng for blastema) of purified AxMLP or equivalent volume of control flow-through fraction was injected into the spinal cord and the blastema to rescue the morpholino effect. The length of the blastema was measured from the amputation plane to the tip at the spinal cord level on 1, 3, 6, 10 and 14 dpa based on the stereoscope images (SZX 16, OLYMPUS). To detect BrdU incorporation, the animals were injected intraperitoneally with 30 μl of 2.5 mg ml −1 BrdU (Sigma) 4 h before collecting the tails at 3 dpa. Fixation, embedding, cryosection, staining and imaging were described earlier. For the quantification, 3 cross-sections of the blastema (200-300 μm posterior to the amputation plane) from four different animals in each condition (FITC/flow-through, FITC/ purified AxMLP, control morpholino/flow-through, control morpholino/purified AxMLP, AxMLP-specific morpholino/flow-through, AxMLP-specific morpholino/ purified AxMLP, respectively) were taken, and the marker-positive nuclei (BrdU + , PAX7 + , MEF2 + or Hoechst + ) on the sections were counted by hand. Newt experiments. Animals. Red-spotted newts, Notophthalmus viridescens, were supplied by Charles D. Sullivan Co. Animals were anaesthetized in 0.1% ethyl 3-aminobenzoate methanesulfonate (Sigma) for 15 min. Forelimbs were amputated above the elbow, and the bone and soft tissue were trimmed to produce a flat amputation surface. Animals were left to recover overnight in an aqueous solution of 0.5% sulfamerazine (Sigma). At specified time points, the uninjured or regenerating limbs were collected. All surgical procedures were performed according to the European Community and local ethics committee guidelines. Protein injection and cell cycle assays in newt limbs. The general condition in the newt experiments: 2 μl of 5 mg ml −1 purified AxMLP protein or equivalent volume of flow-through (AxMLP depleted fraction) was injected into the newt limbs. For EdU labelling, animals were injected intraperitoneally with 50-100 μl of 1 mg ml −1 EdU. To investigate the effect of AxMLP on intact newt limbs, purified AxMLP or flow-through was injected into the uninjured limb twice at day 1 and day 3. EdU was administered daily from day 1 to day 5 (Fig. 3a, top) . To investigate the effect of AxMLP on regenerating limbs, purified AxMLP or flow-through was injected into the regenerating limbs at 7 and 10 dpa (Fig. 3b, top) . EdU was administered daily from 8 to 13 dpa. For labelling myofibre progeny, a H2B-YFP reporter construct was introduced into myofibres before amputation as previously described 15 (Fig. 3c, top) . Cell cycle re-entry was quantified by EdU incorporation in the YFP + myofibre progeny at 13 dpa. Immunohistochemistry. Frozen sections (5-10 μm) were thawed at room temperature and fixed in 4% formaldehyde for 5 min. Sections were blocked with 5% donkey serum and 0.1% Triton-X for 30 min at room temperature. Sections were incubated with anti-GFP (Abcam 6673), anti-PAX7 (DSHB) or anti-MHC (DSHB) overnight at 4 °C and with secondary antibodies for 1 h at room temperature. Antibodies were diluted in blocking buffer and sections were mounted in mounting medium (DakoCytomation) containing 5 μg ml −1 DAPI (Sigma). EdU detection was performed as previously described 15 . An LSM 700 Meta laser microscope with LSM 6.0 Image Browser software (Carl Zeiss) was used for confocal analyses. One in every eight sections was selected and labelled. For PAX7 + satellite cell counting, three sections were randomly selected and counted. For blastema YFP + cell counting, all the sections in the region from regenerate tip to the bone were counted. Statistical analysis. Statistical analyses were performed using GraphPad Prism 6.0 (GraphPad Software). Student's t-test, parametric, two-tail testing was applied to populations to determine the P values indicated in the figures. Significance was considered to have been reached at P values from <0.05. No statistical methods were used to predetermine sample size. In vivo axolotl experiments were not randomized and no blind tests were applied.
Extended Data Figure 3 | AxMLP is classified as a member of the MARCKS family and characterization of its extracellular release in HEK293 cells. a, Amino-acid sequence alignment of AxMLP with sequences from other vertebrates, human, mouse, rat, chick, newt, Xenopus and zebrafish. AxMLP contains three conserved domains: (1) myristoylated N terminus domain; (2) MARCKS homology domain; and (3) effector domain. b, A phylogenetic tree of vertebrate MARCKS family proteins. The tree was constructed by the neighbourjoining method with the ClustalW program. The percentage beside the nodes shows that a node was supported in 1,000 bootstrap pseudo replications. The scale bar indicates evolutionary distance. c, Schematic illustration of His-tagged AxMlp (left) and eGFP-fused AxMlp (right). 3C protease PreScission site was inserted between AxMlp and the tag for both constructs. d, e, AxMLP does not induce significant cell death.
The percentage of GFP-expressing HEK293 cells (d) and absolute number of the cells (e) (n = 16: 4 biological, 4 technical replicates each; mean ± s.d.; centre values as median; whiskers as maximum and minimum, respectively) at the indicated time points of culture. There was no significant difference with Student's t-test between AxMlp-transfected cells and the control in any time points. f, Characterization of anti-AxMLP antibodies by western blot. Cell lysates from HEK293 cells transfected with the indicated plasmids were tested for the full-length AxMLP polyclonal antibody (left) and C-terminal AxMLP polyclonal antibody (right). g, Silver staining of the fractions from AxMLP-His purification. Bovine serum albumin (BSA) was added to purified fraction as a carrier protein. h, AxMLP-His purification analysed by anti-His-tag western blotting. NS, not significant.
